PARASHLTH · NSE,BSE · Multi-Specialty Hospital
Paras Healthcare IPO listed on 28 Oct 2026 on NSE,BSE at ₹720.00, a gain of 3.90% over the issue price of ₹693.00. The IPO was subscribed 2.23x overall.
Paras Healthcare IPO tentative timeline covering IPO opening, closing, basis of allotment, refunds, demat credit, and listing dates.
| Event | Date |
|---|---|
| IPO Open Date | 21 Oct 2026 |
| IPO Close Date | 23 Oct 2026 |
| Basis of Allotment | 26 Oct 2026 |
| Initiation of Refunds | 27 Oct 2026 |
| Credit of Shares to Demat | 27 Oct 2026 |
| Listing Date | 28 Oct 2026 |
Listing day gain
+3.9%
Listed at ₹720 (issue ₹693)
Issue
₹693
Listing
₹720
Current
₹730.8
+5.45% vs issue
Day range
₹706 – ₹748.85
Issue Size
20,923,520 shares
(aggregating up to ₹1,450.00 Cr)
Issue Price
₹660 – ₹693
Face Value
₹1/share
Market Lot
21 shares
Retail Min Investment
₹14,553
Listing At
NSE,BSE
Sale Type
both
Fresh Issue
7,215,007 shares
(aggregating up to ₹500 Cr)
Offer for Sale
13,708,513 shares
(aggregating up to ₹1,300 Cr)
Issue Type
book building
Open Date
21 Oct
Close Date
23 Oct
Allotment
26 Oct
Listing
28 Oct
Last updated: 3 weeks ago
| Date | IPO Issue Price (₹) | GMP (₹) | Est. Listing Price (₹) | Est. Profit Amount (₹) | Est. Profit % | Last Updated |
|---|---|---|---|---|---|---|
| 28 Oct 2026 Latest | ₹693 | ₹13 | ₹706 | ₹13 |
1.88%
|
4:00 AM |
| 28 Oct 2026 | ₹693 | ₹13 | ₹706 | ₹13 |
1.88%
|
3:30 AM |
Showing the 2 most recent GMP entries.
Paras Healthcare IPO GMP & full historyLatest snapshot: 23 Oct 2026
| Category | Subscribed (x) |
|---|---|
| QIB | 3.09x |
| NII | 0.66x |
| bNII (bids above ₹10L) | 0.59x |
| sNII (bids below ₹10L) | 0.8x |
| Retail Investors | 2x |
| Total | 2.23x |
Showing the latest subscription snapshot.
View full subscription historyDharminder Kumar Nagar is the promoter of the company.
New to lot sizes and investment limits? Read our guide on IPO lot size and minimum investment.
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 21 | ₹14,553 |
| Retail (Max) | 13 | 273 | ₹189,189 |
| S-HNI (Min) | 14 | 294 | ₹203,742 |
| S-HNI (Max) | 68 | 1,428 | ₹989,604 |
| B-HNI (Min) | 69 | 1,449 | ₹1,004,157 |
Want to understand how IPO shares are divided between investor categories? Read our guide on IPO reservation structure.
| Category | Shares Offered |
|---|---|
| QIB Shares Offered | 15,692,640 (75.00%) |
|
•
Anchor Investor Shares Offered
|
9,415,584 (45.00%) |
|
•
QIB (Ex. Anchor) Shares Offered
|
6,277,056 (30.00%) |
| NII (HNI) Shares Offered | 3,138,528 (15.00%) |
|
•
bNII > ₹10L
|
2,092,352 (10.00%) |
|
•
sNII < ₹10L
|
1,046,176 (5.00%) |
| Retail Shares Offered | 2,092,352 (10.00%) |
| Total Shares Offered | 20,923,520 (100.00%) |
Established in December 1987, Gurugram-headquartered Paras Healthcare Limited has built a stellar reputation as a highly dominant, clinical specialty-led healthcare provider in Northern India. Operating a sprawling network under the well-known consumer brand "Paras Health," the group has transitioned into a public limited enterprise to anchor a highly anticipated capital market debut.
The company occupies a critical role in India’s tertiary and quaternary healthcare ecosystem. Rather than concentrating solely on hyper-saturated metro markets, Paras Health strategically targets highly demanding macro-regions across five states and one union territory—including major setups in Bihar, Jharkhand, Haryana, Rajasthan, Uttar Pradesh, and Jammu & Kashmir. As of early 2026, the company operates a robust network of eight comprehensive multi-specialty hospitals with an aggregate capacity of 2,211 beds, specializing in high-acuity treatments like advanced neurology, cardiac sciences, oncology, and complex orthopedics.
Demonstrating strong operational scale, the group’s annual revenues scaled past the ₹1,600 crore milestone, paired with robust EBITDA growth driven by rising patient volumes and specialized clinical programs. As the healthcare pioneer refiles its papers for an ₹1,800 crore mainboard initial public offering to fund massive upcoming bed expansions in Ludhiana and Gurugram, it stands out as an institutional powerhouse uniquely primed to ride the structural transformation of Indian medical infrastructure.
Standalone · ₹ in Crores
| Particulars | FY Mar 2025 | FY Mar 2026 | FY Jun 2026 |
|---|---|---|---|
| Total Revenue | 1,314.21 | 1,628.78 | 478.75 |
| Profit After Tax (PAT) | -57.98 | 43.83 | 49.68 |
| EBITDA | 156.46 | 335.58 | 113.48 |
| Total Assets | 1,810.45 | 2,071.14 | 2,202.88 |
| Net Worth | 280.49 | 394.94 | 444.96 |
| Reserves & Surplus | 270.73 | 384.84 | 434.86 |
| Total Borrowing | 727.93 | 854.1 | 1,429.49 |
Revenue & Profit Trend
Key ratios per fiscal period
| Particulars | Mar 2026 | Jun 2026 |
|---|---|---|
| RoE Return on Equity Shows how much profit the company makes on the money shareholders have put in. 15% to 20% is healthy in most industries. | 12.98% | 11.83% |
| RoCE Return on Capital Employed Shows the profit earned on all the money used, shareholder funds plus loans. Matters most for factory and infrastructure heavy companies. | 10.76% | 4.23% |
| RoNW Return on Net Worth Shows the profit earned on the company's own net worth. Steady or rising over 3 years is a good sign. | 12.98% | 11.83% |
| PAT Margin Profit After Tax Margin Out of every ₹100 of sales, how much the company keeps after paying all costs, loan interest and tax. | 2.69% | 10.38% |
| EBITDA Margin Earnings Before Interest, Tax, Depreciation and Amortisation Margin Profit from the main business as a share of sales, before loan interest and tax. Compare it with other companies in the same industry. | 20.6% | 23.7% |
| Debt / Equity Debt to Equity How much the company has borrowed against what shareholders own. Above 1x means the loans are bigger than shareholder funds. | 3.53x | 3.21x |
| P/BV Price to Book Value Tells you if the IPO price is above what the company actually owns. 1x to 3x is usually seen as reasonable. | 17.72x | 15.73x |
Issue-level · at the upper price band
| Particulars | Pre-IPO | Post-IPO |
|---|---|---|
| EPS Earnings Per Share Profit the company earns on each share. Post-IPO EPS is usually lower because the issue adds new shares. | ₹4.34 | ₹18.37 |
| P/E Price to Earnings Tells you if the IPO price is fair for what the company earns. Compare it with listed companies in the same sector. | 159.68x | 37.72x |
| Market Cap Market Capitalisation What the whole company is valued at, at the upper price band. Post-IPO counts the new shares the issue creates. | ₹6,998 Cr | ₹7,498 Cr |
The basis of allotment for Paras Healthcare IPO was finalised on 26 Oct 2026. You can check your allotment status using your PAN number or application number on the MUFG Intime India Pvt.Ltd portal or BSE.
The Paras Healthcare IPO is expected to open in Oct 2026, subject to SEBI approval. Final dates will be updated once announced officially.
The price band for Paras Healthcare IPO is ₹660.00 - ₹693.00 per share.
As per market sources, Paras Healthcare IPO GMP is currently ₹13.00. GMP is tracked daily in the grey market. GMP indicates unofficial demand but does not guarantee listing gains.
The subscription status for Paras Healthcare IPO stands at 2.23x overall.
The listing date for Paras Healthcare IPO is 28 Oct 2026.
No comments yet. Be the first to comment!